Akari Therapeutics (AKTX) Interest Coverage Ratio (2014 - 2026)
Akari Therapeutics recorded quarterly Interest Coverage Ratio of 258.33 in Q1 2026, down 6696.42% quarter-over-quarter from 3.8 in Q4 2025, and down 303.06% year-over-year from 127.21 in Q1 2025.
Akari Therapeutics' Interest Coverage Ratio history runs 5 years deep, the most recent figure standing at 258.33 for Q1 2026.
- In Q1 2026, Interest Coverage Ratio fell 303.06% year-over-year to 258.33; the TTM figure through Mar 2026 stood at 27.3 (down 511.09% YoY), while the FY2025 annual figure was 18.2, up 99.75% from the prior year.
- Interest Coverage Ratio came in at 258.33 for Q1 2026 at Akari Therapeutics, down from 3.8 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 3.8 in Q4 2025 to a low of 258.33 in Q1 2026.
- A 3-year average of 80.28 and a median of 61.79 in 2025 frame the typical range for Interest Coverage Ratio.
- Across the five-year window, Interest Coverage Ratio jumped 57.29% in 2025 and slumped 303.06% in 2026, its largest moves.
- Akari Therapeutics' Interest Coverage Ratio stood at 4.0 in 2024, then grew by 4.94% to 3.8 in 2025, then sank by 6696.42% to 258.33 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 258.33, 3.8, and 61.19 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 11.50 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 49.84 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.88 |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | -36.50 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -258.33 |
| Dec 31, 2025 | -4.46 |
| Sep 30, 2025 | -61.19 |
| Jun 30, 2025 | -62.38 |
| Mar 31, 2025 | -64.09 |
| Dec 31, 2024 | -4.00 |
| Sep 30, 2024 | -42.42 |
| Jun 30, 2024 | -146.06 |
| Dec 31, 2015 | -0.70 |
| Sep 30, 2015 | 7.64 |
| Jun 30, 2015 | 502.11 |
| Mar 31, 2015 | -363.18 |
| Dec 31, 2014 | 523.51 |
| Sep 30, 2014 | -75.65 |